Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Russia
Andrey Aleshkin, Sc.D.-biology, now is head of the Laboratory for Clinical Microbiology and Biotechnology of Bacteriophages of Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology (MRIEM) and chief scientist in Bphage LLC. He received his Ph.D.-medicine in medical cybernetics at Pirogov Russian National Medical University, MBA in marketing at Lomonosov Moscow State University, Sc.D. in biotechnology and microbiology at Gabrichevsky MRIEM. Currently Dr. Andrey Aleshkin’s research focuses on the clinical safety and specific activity of bacteriophages as probiotics and decontaminating agents for food products. He has published more than 60 papers in peer-reviewed journals and 30 patents in Russia.
The more prevalent bacterial strains increasing in numbers are those with high thermostability, resistant to many present-day antibiotics and disinfectants, those which are capable to cause foodborne infections (FBI) with high mortality incidence among patients. In this situation using the accumulated Russian experience it is logical to propose a worldwide development of a renewed class of antibacterial agents based on bacteriophages. Since 1930s in different parts of the Soviet Union a lot of doctors began to use phages in human prophylaxis and therapy. Later in the 1960s four Institutes for Vaccines and Sera (in Ufa, Tbilisi, Nizhnii Novgorod, and Perm’) began to produce a dozen medicinal compounds based on several individual species of bacteriophages or their combinations which were used to treat and prevent acute intestinal infections and decompensated forms of dysbacteriosis and to control causative agents of certain pyoinflammatory infections. In recent years in the Russian Federation phage cocktails are administered intracorporeally or locally: wound and mucosa irrigation, introduction in the cavities of vagina, urinary bladder, ear, paranasal sinus, eye conjuctiva and also in the drained cavities: abdominal, and pleural, in the cavities of abscesses after the pus was removed. Therefore, world scientists should not neglect these clinical results when designing any future studies. We have developed a phagebiotic for prophylaxis of FBI caused by E.coli, Shigella flexneri, Shigella sonnei, Salmonella enterica, Listeria monocytogenes or Staphylococcus aureus, and investigated its effectiveness against infection caused by the non-pathogenic Lac (-) strain of E.coli in animal and human trials